# **DirectConnect**

**Inside Yale Cancer Center** 

#### October 20, 2023

#### Dear Colleagues,

A month ago, when talking to a friend, I commented that our country is more divided than ever, and our broader world faces an overwhelming array of challenges. In the past two weeks, the state of the world has become that much more unstable. The horrific events in the Middle East have shocked us all, and there is deep worry and uncertainty as to what will be unfolding in the weeks and months ahead. Regardless of our nationalities, ethnicities, race, political views, beliefs, or general sensibilities, it is impossible to ignore the vast suffering – the loss of life, the physical pain, the psychological torment, and the huge economic consequences.

Sadly, the crisis in the Middle East is by no means the only area of conflict. The war in the Ukraine is nearly two years old and remains an ongoing struggle for the people of that region; there is civil war in Sudan; and rampant violations of human rights in many parts of the world. Here, at home, we face the problems of gun violence, school shootings, and hate crimes. Daily, we learn about lives lost, we shake our heads, and we do not know when it will end.

I have often wondered if pervasive suffering and death evoke a particular kind of distress for people who have committed themselves to cancer treatment and research than for some others. We spend endless hours taking care of patients, conducting clinical trials, and devoting ourselves to scientific inquiry. We try to save lives – one patient at a time – and try to minimize suffering for every individual. That commitment, layered with the widespread death and suffering of the past two weeks, generates complex feelings of loss and grief.

For those of you who have family and friends living in the Middle East, the past two weeks must have been profoundly traumatic. My heart goes out to all of you, to the large number of our colleagues who are both worried and disturbed by this conflict, and the others unfolding around world. For far too many people, these situations are not abstract constructs, but an ongoing reality.

I am a fundamentally optimistic person. I believe that we will see a better time in the years ahead and that it can help if we focus on where we can act. We can continue our comprehensive work to eliminate mortality and suffering from cancer, and we can focus on our own communities to ensure that they are safe, just, and fundamentally kind places to live.

#### Eric P. Winer, MD

Director, Yale Cancer Center President and Physician-in-Chief, Smilow Cancer Hospital

# Yale NewHaven **Health**

Smilow Cancer Hospital



A Comprehensive Cancer Center Designated by the National Cancer Institute

#### **News Center**










HPV Discovery Yields Breakthrough in Understanding Protein Activity



**Read More** 



#### **Announcements**

### Ellie Proussaloglou, MD, Joins Center for Breast Cancer

Ellie Proussaloglou, MD, Assistant Professor of Surgery (Oncology, Breast), cares for patients as part of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center in New Haven and Guilford. Dr. Proussaloglou completed her fellowship in breast surgery at



Yale and her residency in Obstetrics and Gynecology at Brown University/Women & Infants Hospital. She received her medical degree from the University of Chicago Pritzker School of Medicine.

Her joint training in breast and gynecologic surgery allows her to provide comprehensive counseling about breast cancer care, along with a thorough understanding of the gynecologic and sexual side effects of therapy. Her research focuses on decisions facing patients undergoing surgery or high-risk screening, with an emphasis on the financial impacts of care. She has led interdisciplinary research focused on survivorship, quality of life, and sexual health after a cancer diagnosis, including novel research on financial toxicity in BRCA carriers. Dr. Proussaloglou has local and national advocacy experience as the Legislative Chair for District 1 (New England) of the American College of Obstetricians and Gynecologists. She is particularly passionate about caring for high-risk genetic mutation carriers and young women with breast cancer.

### Head and Neck Cancer Program Welcomes Sara Pai, MD, PhD

Sara Pai, MD, PhD, recently joined the Head and Neck Cancer Program at Smilow Cancer Hospital and Yale Cancer Center from the Division of Surgical Oncology at the Massachusetts General Hospital/Harvard Medical School. Dr. Pai completed the MD/PhD program at Johns Hopkins University School of Medicine, where she obtained her PhD training in cancer immunology and



vaccines. She did her residency in otolaryngology-head and neck surgery at Johns Hopkins Hospital.

Dr. Pai is a surgeon-scientist who has dedicated her career to advancing the clinical care of patients with human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) through the development of novel immunotherapeutic approaches. Her research focuses on a better understanding of how HPV can evade the immune system and reactivation of the host immune response against the virus and its related cancer cells


through novel immunotherapeutic strategies. She is recognized both nationally and internationally as an expert in HPV-associated head and neck cancers and cancer immunotherapy. Dr. Pai leads several clinical

# A Therapy Dog: Making a Difference in Cancer Care



Read More

# 5 Things You Need to Know About Breast Cancer Right Now



**Read More** 

## Yale New Haven Health Check: National Breast Cancer Awareness Month



**Watch Now** 

Dr. Stacey Stein on Key Considerations
When Selecting an Immunotherapy
Approach in HCC



immunotherapy trials and has over 80 publications in peer-reviewed journals.

#### **Notables**

Susan J. Baserga, MD, PhD, MPhil, William H. Fleming, MD, Professor of Molecular Biophysics & Biochemistry and Professor of Genetics and of Therapeutic Radiology, and a member of Yale Cancer Center's Genomics, Genetics, and Epigenetics Research Program, and Emily Ai-hua Wang, MD, MAS, Professor of Medicine (General Medicine) and of Public Health (Social & Behavioral Sciences), and a member of Yale Cancer Center's Cancer Prevention and Control Research Program, have been elected to the National Academy of Medicine (NAM), which recognizes individuals for outstanding professional achievement and commitment to service.

Earlier this week, **Tara Sanft, MD**, Associate Professor of Medicine (Medical Oncology), Chief, Patient Experience Officer, and Medical Director of the Smilow Cancer Hospital Survivorship Clinic, presented in a panel at the **Cancer Survivorship Summit**, a special event hosted by U.S. Representative from Florida and breast cancer survivor, **Debbie Wasserman Schultz**. Dr. Sanft joined First Lady, **Dr. Jill Biden**, who was the Keynote Speaker, as well as **Katie Couric** and **Martina Navratilova** as one of many notable guest speakers at the Summit.

Amer Zeidan, MBBS, Associate Professor of Medicine (Hematology), Director, Early Therapeutics Research, Hematology, and Interim Chief, Hematologic Malignancies, co-chaired the first meeting of the Society of Hematologic Oncology-Middle East and North Africa Chapter (SOHO\_MENA) held at the Lebanese National Library in Beirut, Lebanon September 28-29 and gave two talks about AML and MDS. Dr. Zeidan also co-chaired the second meeting of Controversies in MDS AND AML (COMydAL) of the International Academy for Clinical Hematology (IACH) in Paris, France last week and also presented on MDS and AML.

**Qin Yan, PhD,** Professor of Pathology and Co-Leader, Genomics, Genetics & Epigenetics Research Program, will receive the **Outstanding Investigator Award** from the **American Society for Investigative Pathology (ASIP)** at its upcoming joint meeting in Salt Lake City with the American Society for Matrix Biology and The Histochemical Society. The ASIP Outstanding Investigator Award recognizes mid-career investigators with demonstrated excellence in experimental pathology research.

The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its 2023 commitment to fund breast cancer research in 2023-2024, including eight grants at Yale Cancer Center and Smilow Cancer Hospital. Currently receiving funding through the BCRF are Kim Blenman, PhD, MS, Mehra Golshan, MD, MBA, Melinda Irwin, PhD, MPH, Adriana Kahn, MD, Ian Krop, MD, PhD, Lajos Pusztai, MD, David Rimm, MD, PhD, and Eric Winer, MD, to support their research. Learn more

The Yale Myeloma team, **Drs. Natalia Neparidze**, **Terri Parker**, **Noffar Bar**, **Sabrina Browning**, and **Elan Gorshein**, participated in the **International Myeloma Society Meeting** in Athens, Greece in September. Together with Yale Medical Student Mansen Yu and Medical Resident Tinatin Muradashvili,



**Watch Now** 

#### **How a Time Out Can Help Address Bias**



**Read More** 

# Yale-Led Research Explains Why Many Cancer Drugs Fail During Clinical Trial Testing



**Read More** 

### **Smilow Shares Breast Cancer Education**

Series (CME) - Surgical Advances



**Watch Now** 

CT Breast Cancer Survivor Helps Single

Mothers with Disease Pay for Housing

the team presented data on the role of metabolic and viral syndromes in monoclonal gammopathy.

Congratulations to the following Smilow Cancer Hospital Advanced Practice Providers who have achieved their APP Clinical Ladder II or III: APP Clinical Ladder II:

- Emily Kopas, APRN (Smilow Cancer Hospital at Greenwich)
- Javin Brita, PA (Cancer Survivorship/Breast Medical Oncology)
- Jackie Lagasse, APRN (Smilow Cancer Hospital at Waterford)
- Maureen McGlennon, APRN (Stem Cell Transplantation/Cellular Therapy)
- Lisa Rivera, APRN (Stem Cell Transplantation/Cellular Therapy)


#### **APP Clinical Ladder III:**

- Amy Barile-Pugliese, APRN (Stem Cell Transplantation/Cellular
- Karen Hammond, APRN (Smilow Cancer Hospital at Waterbury)

### **Center for Community Engagement and Health Equity (CEHE)**

#### **Health Equity Bootcamp**

The Yale School of Medicine Office of Health Equity Research will hold their second annual Health Equity Bootcamp this Monday, October 23 from 9am to 3:10pm at Yale West Campus. The focus of the event is on methods and measurement of race and ethnicity data in research, EHR-based collection and use of social needs and social determinants of health, enhancing sexual orientation and gender identity data collection, and collecting and using SSDOH data in community research settings. All are welcome to attend, junior



faculty and trainees are particularly encouraged to participate. Registration can be completed at this link.

#### **Survey on Clinical Trial Diversity**

The Early Phase Clinical Trial Program and CEHE want to better understand barriers to early phase trial diversity within Smilow Cancer Hospital. Please help by taking a few minutes to complete a survey to better understand Smilow provider perspectives. Upon completion, you can choose a \$25 gift card or a donation on your behalf to a local food pantry or cancer support organization (up to \$8,000) for your time. Please click here to complete the survey.

#### **Employee Profile: Mia Talamelli**



Read More

What's New in Targeted Lung Cancer

Treatment?



Watch Now

**Q&A: How PCPs Can Improve Care for** 

Their Transgender Patients



Many transgender people experience harm in clinical settings across the country when their identities and experiences are known to clinicians.

Ash B. Alpert, MD, MFA

Healio

Read More









Meet Isaac Kim, MD, PhD, MBA, Chief of Urology, who cares for patients with prostate cancer. A recent patient shared comments

about Dr. Kim: "Dr. Kim was remarkable. Dr. Lokeshwar and other residents who checked in on me were thorough, kind, and patient. Grateful!"





various Smilow locations as part of the Yale New Haven Health System. Just over a year ago, Mia joined Yale Cancer Center in the section of Hematology as a Senior Administrate Assistant. She found the transition to be a smooth one and enjoys the opportunity to interact with former colleagues and continue those relationships.

"I am very grateful that I found this position," said Mia. "Everyone I work with is so kind and we support each other as much as we can. It is a family

environment, and we are all working every day with the same goal of supporting the team. It can be challenging juggling multiple schedules, but it's rewarding when it all works out and I am able to figure out a problem."

Mia supports five physicians within Hematology and handles everything from travel, to scheduling meetings and processing expense reports. She commented that every day is different based on what the needs of each physician are and where support is needed. With a background in Art History, Mia enjoys the creative thinking required to balance busy schedules and appreciates knowing that having their calendars taken care of allows the physicians to focus solely on what needs to be done for their patients.

Richard Carr, Supervisor, Administrative Services for the Section of Hematology commented, "I have been so amazed at how quickly Mia got herself up to speed with everything that we do this past year. We are so fortunate for her to have joined our team."

Alfred Lee, MD, PhD, Professor of Medicine (Hematology) and Chief of the Classical Hematology Program, commented, "Every now and then, you meet people who give 10000% of themselves in their professions and are so far above-and-beyond in their talents and abilities—and who, on top of this, are so incredibly pleasant, positive, and wonderful to be around hat you know they must be superhuman. Mia Talamelli is one of those people. Day in and out, she supports five extremely busy faculty and somehow makes each one of us feel like we are the only one. If you were to count up the number of times she has helped our faculty, staff, fellows, and patients, you would see her impact is truly immeasurable."

#### **Recent Publications**

Youngblood MW, Erson-Omay Z, Li C, Najem H, Coşkun S, Tyrtova E, Montejo JD, Miyagishima DF, Barak T, Nishimura S, Harmancı AS, Clark VE,

Duran D, Huttner A, Avşar T, Bayri Y, Schramm J, Boetto J, Peyre M, Riche M, Goldbrunner R, Amankulor N, Louvi A, Bilgüvar K, Pamir MN, Özduman K, Kilic T, Knight JR, Simon M, Horbinski C, Kalamarides M, Timmer M, Heimberger AB, Mishra-Gorur K, Moliterno J, Yasuno K, Günel M. Super-enhancer hijacking drives ectopic expression of hedgehog pathway ligands in meningiomas.

Nat Commun. 2023 Oct 7;14(1):6279.

Domkowicz B. Bointdujour Lim B. Miguez S. Lee V. Jones

Read More



#### **Read More**

Smilow Cancer Hospital and Yale Cancer Center have been recognized by Becker's Hospital Review as an outstanding oncology program for accelerating innovation, discovery, and greater access to care. Only 100 hospitals and health systems were featured by Becker's as premier providers of cancer care across the nation.

Among the standouts for Smilow Cancer Hospital and Yale Cancer Center are the collaborations between scientists and physicians as the largest provider of cancer care in the state of Connecticut. Also highlighted were initiatives to minimize mortality from all types of cancer, reduce disruption to patient's lives, and eliminate barriers to cancer care.



#### **Read More**

Our Quality and Patient Safety team reads all comments submitted by our patients. We

view feedback as constructive; it helps us improve and meet the needs of our patients, and it gives us opportunities to share kudos to those mentioned by name. Your voice matters.



Bosenberg M, Abramson DH, Shoushtari AN, Kluger H, Francis JH, Sznol M, Bakhoum MF.

Determinants of overall survival in patients with metastatic uveal melanoma.

Cancer. 2023 Oct 15;129(20):3275-3286.

**Read More** 

Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman LE, Flora DB, Friese CR, Galsky MD, Gonzalez CJ, Grivas P, Gupta S, Haynam M, Heilman H, Hershman DL, Hwang C, Jani C, Jhawar SR, Joshi M, Kaklamani V, Klein EJ, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Labaki C, Lammers PE, Lathrop KI, Lewis MA, Li X, Lopes GL, Lyman GH, Makower DF, Mansoor AH, Markham MJ, Mashru SH, McKay RR, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen RH, Nonato TK, O'Connor TL, Panagiotou OA, Park K, Patel JM, Patel KG, Peppercorn J, Polimera H, Puc M, Rao YJ, Razavi P, Reid SA, Riess JW, Rivera DR, Robson M, Rose SJ, Russ AD, Schapira L, Shah PK, Shanahan MK, Shapiro LC, Smits M, Stover DG, Streckfuss M, Tachiki L, Thompson MA, Tolaney SM, Weissmann LB, Wilson G, Wotman MT, Wulff-Burchfield EM, Mishra S, French B, Warner JL, Lustberg MB, According MK, Shah DP; COVID-19 and Cancer Consortium.

Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: a COVID-19 and cancer consortium (CCC19) cohort study.

Elife. 2023 Oct 17;12:e82618.

**Read More** 

Snyder RA, Burtness B, Cho M, Del Rivero J, Doroshow DB, Hitchcock KE, Kalyan A, Kim CA, Lukovic J, Parikh AR, Sanford NN, Singh B, Shen C, Shroff RT, Vijayvergia N, Goodman KA, Kunz PL.

The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership.

J Natl Cancer Inst. 2023 Oct 9;115(10):1132-1138.

**Read More** 

Ginapp CM, Greenberg NR, MacDonald-Gagnon G, Angarita GA, Bold KW, Potenza MN.

"Dysregulated not deficit": A qualitative study on symptomatology of ADHD in young adults.

PLoS One. 2023 Oct 12;18(10):e0292721.

**Read More** 

Oh C, Buckley PM, Choi J, Hierro A, DiMaio D.

Sequence-independent activity of a predicted long disordered segment of the human papillomavirus type 16 L2 capsid protein during virus entry.

Proc Natl Acad Sci U S A. 2023 Oct 17;120(42):e2307721120.

**Read More** 

Bhattacharjee D, Bakar J, Chitnis SP, Sausville EL, Ashtekar KD, Mendelson BE, Long K, Smith JC, Heppner DE, Sheltzer JM.

Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor.

Cell Chem Biol. 2023 Oct 10:S2451-9456(23)00332-X.

**Read More** 

Blair LM, Juan JM, Sebastian L, Tran VB, Nie W, Wall GD, Gerceker M, Lai IK, Apilado EA, Grenot G, Amar D, Foggetti G, Do Carmo M, Ugur Z, Deng D, Chenchik A, Paz Zafra M, Dow LE, Politi K, MacQuitty JJ, Petrov DA, Winslow MM, Rosen MJ, Winters IP.

Oncogenic context shapes the fitness landscape of tumor suppression. *Nat Commun.* 2023 Oct 12;14(1):6422.

**Read More** 



#### **Read More**

Recently on Yale Cancer Answers, Dr.
Richard Edelson discussed his recent
Cancer Moonshot Award supporting the
development of anti-cancer vaccines using
mRNA technology. Listen on Connecticut
Public Radio or download our podcast from
iTunes.



#### **Read More**

Earlier this month, Smilow Cancer Hospital celebrated the opening of a new location for breast cancer care in Bridgeport, CT at 226 Mill Hill Avenue. Dr. Melanie Lynch and Dr. Monica Valero will see patients at the new location.



Morris JC, Gombos EA.
Onco-Hospitalists Bring Value to Patient Care.
The Hospitalist.
Read More

#### **Funding and Award Opportunities**

### 2024 Pershing Square Sohn Prize for Young Investigators in Cancer Research

The Pershing Square Sohn Prize for Young Investigators in Cancer Research provides greater New York City area-based early career scientists the freedom to take risks and pursue their boldest research at a stage when traditional funding is lacking. As of 2023, Prize winners each receive \$250,000 a year for three years, totaling \$750,000. At least six prizes are awarded annually.

Letter of Intent Due: October 30, 2023

**Read More** 

### The Pershing Square Sohn Cancer Research Alliance 2024 Prize for Rising Leaders in Cancer Research

A prize of \$250,000 per year for three years will be awarded to at least six New York City area-based scientists. The Prize empowers researchers to pursue novel, high-risk/high-reward cancer research at a stage when traditional funding is lacking. Applicants must have between two and six years of experience running their own laboratories by the award start date (July 2024), hold a PhD, MD, or MD-PhD (or degree equivalent), and be affiliated with a research institution in the greater New York City area.

Letter of Intent Due: October 30, 2023

**Read More** 

### Leveraging Social Networks to Promote Widespread Individual Behavior Change (R01)

The purpose of this NOFO is to invite basic observational or experimental behavioral and/or social science R01 applications that test how intrapersonal and interpersonal mechanisms of behavior change interact with, influence, or are influenced by characteristics of social networks, with implications for health. Research supported through this NOFO will examine at least two levels of analysis: interpersonal processes and social network characteristics.

Application Deadline: November 3, 2023

**Read More** 

### AACR - Quad W Foundation Sarcoma Research Fellowship in memory of Willie Tichenor

AACR-Quad W Foundation Sarcoma Research Fellowship in Memory of Willie Tichenor represents a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct translational or clinical sarcoma research and to establish a successful career path in this field. The fellowship provides a one-year grant of \$50,000 to support the salary and

benefits of the fellow while working on a mentored sarcoma research project. **Application Deadline:** November 8, 2023 **Read More** 

#### Investigator-Initiated Research in Genomics and Health Equity (R01)

The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations.

Application Deadline: November 8, 2023

**Read More** 

Read More

Last week, Roy S. Herbst, MD, PhD, Deputy Director of Yale Cancer Center and Chief of Medical Oncology at Smilow Cancer Hospital, attended the 27th Friends of Cancer Research Cancer Leadership Awards in Washington, DC. Congresswoman Debbie Dingell was honored with the Marlene A. Malek Public Service Award in recognition for her advocacy for patients with cancer and their families.



#### **Read More**

On Saturday, September 30, members of Team Lion Heart participated in their 17th annual team walk in Central Park and gathered for dinner in New York City. Rachel Perry, PhD; Stacy Malaker, PhD; and Arnaud Augert, PhD, shared passionate and informative presentations highlighting their research, which was funded by Lion Heart.



#### Read More

Meet Avanti Verma, MD, head and neck surgeon. Dr. Verma cares for patients with benign and cancerous tumors of the head and neck, including thyroid and salivary diseases, and prioritizes the aesthetic and functional outcomes of her patients.

A recent patient of Dr. Verma's shared: "The

ACRA for Diversity and inclusion in Breast Cancer Research

This award is designed with the primary goal of increasing diversity in the oncology workforce and cancer research. Awards will be given to mid-career investigators who are members of racial and/or ethnic groups traditionally excluded in academic medicine and biomedical research, and who wish to conduct original breast cancer research not currently funded.

Application Deadline: November 16, 2023

**Read More** 

### Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21)

The purpose of this FOA is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

**Application Deadline:** November 17, 2023

**Read More** 

### Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01)

The purpose of this FOA is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

**Application Deadline:** November 17, 2023

**Read More** 

### Advanced Development of Informatics Technologies for Cancer Research and Management (U24)

The purpose of this FOA is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities.

Application Deadline: November 17, 2023

**Read More** 

### **Sustained Support for Informatics Technologies for Cancer Research and Management (U24)**

The purpose of this FOA is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer

research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

Application Deadline: November 17, 2023

Read More

#### **AACR - Bristol Myers Squibb Midcareer Female Investigator Grant**

The AACR-Bristol Myers Squibb Midcareer Female Investigator Grant represents a joint effort to encourage and support mid-career female physician-scientists and researchers to conduct immuno-oncology research and to foster their career advancement toward becoming a senior investigator. Research projects may be translational and/or clinical in nature with a focus on immuno-oncology.

Application Deadline: November 21, 2023 1:00 PM


Read More

Smilow ENT (ear, nose, and throat) staff works extremely well together. They show compassion and medical knowledge. Dr. Verma was outstanding surgeon and very kind."



#### **Read More**

On Yale Cancer Answers, Dr. Mehra
Golshan, Professor of Surgery and Dr. Parisa
Lotfi, Assistant Professor of Radiology and
Biomedical Imaging, discussed the screening
and detection of breast cancer, as well as
advances in treatment options in honor of
Breast Cancer Awareness Month.



#### **Read More**

We are proud to partner with the National Brain Tumor Society on their DNA Damage Response Consortium!

Congratulations to our 8 faculty funded by @BCRFcure: Dr. Kim
Blenman; @MehraGolshan; @mirwin\_yale;
@AdrianaKahnMD; Dr. Ian Krop; Dr. Lajos
Pusztai; @RimmPathology; @DrEricWiner

"The pace of scientific discovery keeps getting faster and faster. I'm

#### **Lion Heart Fund for Cancer Research Grant Opportunity**

Yale investigators are encouraged to submit proposals of innovative, highpotential projects requiring pilot funding. Projects may be in any area of breast cancer research – basic, translational, clinical, outcomes and population science are all welcomed from any discipline or group of disciplines.

Funding will be \$50,000 for a one-year project. The number of projects funded will depend on the amount of funds raised the preceding year but is estimated at two (2) projects for the 2024 cycle.

**Proposal Deadline:** November 27, 2023. Any questions, please reach out to **David Stern**.

**Read More** 

#### 2024 ACS IRG Pilot Grant

The purpose of this grant is to provide pilot funds (up to \$40,000 total for one year) for the initiation of promising new projects or novel ideas by Yale Assistant Professors so that they can obtain preliminary results to enable them to compete successfully for national cancer research grants. These grants will support all potential areas of cancer research including basic, clinical, computational, population and epidemiology, prevention/control, implementation science and translational cancer research.

Internal Submission Deadline: November 27, 2023 Read More

ixeau more

### Understanding and Mitigating Health Disparities experienced by People with Disabilities caused by Ableism (R01 Clinical Trial Optional)

The goal of this NOFO is to encourage research to understand the impact of ableism on health outcomes. Research on the underlying mechanisms by which ableism adversely influences the health of persons with disabilities (PWD), as well as developing and/or testing interventions at a community or health systems level to mitigate adverse health effects of ableism are high priority.

Application Deadline: November 29, 2023

**Read More** 

### Center for Exposome Research Coordination to Accelerate Precision Environmental Health (U24)

This NOFO solicits applications for establishing a Center for Exposome Research Coordination (CERC) that will serve the broad biomedical research community by coordinating and advancing exposome research to accelerate precision environmental health. The CERC will engage existing and ongoing exposome initiatives around the globe to promote methodological advancement and best practices, provide training and education, and foster national and international collaborations.

Application Deadline: November 30, 2023

**Read More** 

#### **CRI Clinic & Laboratory Integration Program (CLIP)**

CLIP provides catalytic support for the translation of basic laboratory discoveries into novel therapies that can be tested in patients. CRI is pleased to announce an increase in the award amount for new CLIP grants. Awards now provide up to \$300,000 over two years.

Application Deadline: December 1, 2023

Read More

#### **CRI Clinical Innovator Grant**

The Clinical Innovator provides funding for clinician-scientists aiming to launch innovative phase I/II or phase II clinical studies using novel immunotherapies. In addition to the merits of the clinical and scientific rationale, studies will be selected based on their novelty, feasibility, and clinical impact.

Application Deadline: December 1, 2023

Read More

optimistic that in the next five to 10 years, we'll have even more groundbreaking treatments." @DrEricWiner shares with @OprahDaily.

.@cececalhounMD shares how using an adaptable tool created to help teams spot and address bias in real time can reduce medical errors and counter the sometimes-deadly effects of #bias in #healthcare.

Congratulations to Dr. Haris Mirza
@pathmirza, recipient of the Clinical
Scientist Research Career Development
Award from @theNCI.

.@NIH and @US\_FDA have renewed a \$20M grant for the Yale Tobacco Center of Regulatory Science (TCORS), led by Dr. Suchitra Krishnan-Sarin @KrishnanSarin and Dr. Stephanie O'Malley.

.@Dr\_AmerZeidan
@YaleHematology presented
#GrandRounds to share updates on current
and investigational therapies for lower and
higher risk #myelodysplastic syndromes.
Watch now <a href="http://youtube.com/watch?">http://youtube.com/watch?</a>

Dr. Michael Cecchini
@Cecchini\_OncMD will present
clinical outcomes for the
#cholangiocarcinoma cohort of a Phase 2
study of Olaparib with translational data from
the trial today at #Targets23.



In addition to co-chairing the 2nd meeting of Controversies in Acute Leukemias and Myelodysplastic

Syndromes of the @TheIACH, @Dr\_AmerZeidan presented two talks about #MDS and #AML.

"The beauty of science lies in its ability to surprise us. This study breaks the mold by revealing a case where the magic of protein activity lies not in its sequence, but in its length." Dr. Daniel DiMaio shares new #HPV discovery @YaleGenetics



The @YaleCancer Cancer
Prevention and Control Research
Program welcomes Vin Zhou, PhD

Rising Tide Foundation for Clinical Cancer Research

RTFCCR's primary consideration in granting support is given to innovative, patient-centered clinical research. RTFCCR funds clinical trials within the focus areas: Improved Patients Outcomes; Science of Early Detection and Intervention; Advancing Cancer Research in Underserved Areas

Letter of Intent Due: December 5, 2023

**Read More** 

### Public Health Communication Messaging about the Continuum of Risk for Tobacco Products (U01)

The purpose of this NOFO is to invite applications for a Research Project (U01) that will utilize health communication research to better understand the impact that messaging about the continuum of risk for tobacco products may have on various segments of the population.

Application Deadline: December 6, 2023

**Read More** 

### Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01)

The purpose of this NOFO is to support Implementation Science for Cancer Control in People Living with HIV (PLWH) in Low- and Middle-Income Countries (LMICs) to accelerate the integration of evidence-based cancer control interventions for PLWH by leveraging existing HIV treatment and prevention infrastructure.

Application Deadline: December 15, 2023

**Read More** 

Flogram welcomes Am Zhou, Flib,

Assistant Professor of Biostatistics.

#### Calendar

### Yale CCEH Rising Stars in Hematology Series

October 20, 2023 12:00 PM

Zoom

Multi-modal profiling of human fetal liver hematopoietic stem cells reveals the molecular signature of engraftment

Kim Vanuytsel

**Learn More** 

## Special Lecture in Virus Biology in honor of Dr. Brett Lindenbach

October 21, 2023 4:00 PM

Marsh Auditorium, 260 Whitney Ave From Yellow Fever to Hepatitis C and back... and beyond

Dr. Charles Rice

**Learn More** 

#### **Yale Cancer Answers**

October 22, 2023 7:30 PM

WNPR 90.5

Breast Cancer Awareness Month

Maryam Lustberg, MD, MPH Learn More

#### Radiobiology and Genome Integrity (RGI)

**Research Program Seminar** 

October 23, 2023 11:00 AM

An elevated rate of whole-genome duplication events in cancers from Black patients

Leanne Brown, MD; Sarah Thompson

Learn More

#### Yale Infectious Diseases, MEAETC, Yale

**HIV Research** 

October 23, 2023 4:00 PM

The Anlyan Center, Auditorium

A discussion with Adam Vastillejo, "The
London Patient"

**Learn More** 

Yale Center for Research on Aging Y-Age Symposium 2023

October 24, 2023 8:00 AM

193 Whitney Ave

**Learn More** 

The Anlyan Center, Auditorium

Stress Mechanisms and the Evolution of
Novel Cell Types

Gunter Wagner, PhD

**Genetics Department Seminar Series** 

Palliative Care Journal Club October 24, 2023 12:00 PM

October 24, 2023 11:30 AM

**FMP 132** 

**Learn More** 

Massage Therapy for Hospitalized Patients Receiving Palliative Care Melissa Mosley, MD

Laava Maya

**Learn More** 

Department of Pathology Innovation and Entrepreneurship Seminar Series October 24, 2023 12:00 PM

Brady Memorial Laboratory

Ranjit Bindra, MD

Learn More

Palliative Care Case Conference

October 24, 2023 4:00 PM

Zoom and FMP618 Conf Room

Navigating patient-centered, End-of-Life

Care for young women with profound

disabilities; A Collaborative, Interdisciplinary

effort.

Nora Segar, MD, PH; Abby Ballerini, LCSW

**Learn More** 

Human and Translational Immunology

**Seminar Series** 

October 24, 2023 4:00 PM

**Brady Memorial Library** 

Novel monogenic inflammatory lower disease genes: 'SYK'ening and others

Aleixo Muise, MD, PhD

**Learn More** 

Virtual Survivorship Series October 24, 2023 5:30 PM

Zoom

Young Women with Breast Cancer

Learn More

Engineering Immune Signaling for Cancer

**Therapy** 

October 25, 2023 12:00 PM

100 College St

Center for Systems and Engineering Immunology Seminar Series

Xiaolei Su, PhD

#### **Learn More**

Endocrine Workshop

October 25, 2023 4:00 PM

Fitkin Memorial Pavilion

My Approach to Thyroid Cancer

Sachin Majumdar Jr, MD

Learn More

**YCC/Smilow Cancer Hospital Town Hall** 

October 25, 2023 5:00 PM

Zoom

Kevin Billingsley, MD, MBA; Kim Slusser,

RN, MSN; Lori Pickens, MHA; Pamela

Sutton-Wallace, MPH

**Learn More** 

**Immunobiology Seminar Series** 

October 26, 2023 10:30 AM

The Anlyan Center

Adventures in viral immunology

Jonathan Yewdell, MD, PhD

**Learn More** 

**Yale Cancer Center Grand Rounds** 

October 27, 2023 9:00 AM

Smilow Auditorium, 55 Park St

What is Ethical Leadership and How Can We

Develop It?

Ira Bedzow, MD

**Learn More** 

**Center for Thoracic Cancers Seminar** 

Series

October 27, 2023 12:00 PM

**Brady Memorial Laboratory** 

Neoadjuvant chemoimmunotherapy for

NSCLC: Promises, challenges, and the

quest for better responses

Brendon M. Stiles, MD

**Learn More** 

**Yale Cancer Answers** 

October 29, 2023 7:30 AM

Aerobic Exercise Relieves Pain for Ovarian

Cancer Survivors

WNPR 90.5

Leah Ferrucci, PhD, MPH and Anlan Cao

**Learn More** 

**Cancer Metabolism Symposium** 

November 1, 2023 8:00 AM

55 Park St

Metabolic Disease and Cancer; Metabolic Interaction in the Tumor Microenvironment;

Targeting Call Matabaliam in Canaari Canaari

Metabolism Techniques, Resources and
Initiatives

**Learn More** 

General Internal Medicine Grand Rounds November 2, 2023 7:30 AM

Zoom

Safe and Effective Use of Opioids in Palliation

Elizabeth Prsic, MD

**Learn More** 

Pharmacology Seminar Series November 2, 2023 12:30 PM

Brady Memorial Laboratory
From mutations to small molecules: lessons
learned from Protein Phosphatase 2A

Goutham Narla Learn More

The 11th Annual RNA Center Retreat November 3, 2023

Marsh Hall, 360 Prospect St

**Learn More** 

#### Share your news!

Please submit your recent publications, awards, and grant announcements to:

#### Renee Gaudette

Director, Public Affairs and Communications

Yale Cancer Center | 333 Cedar Street, New Haven, CT 06520

Unsubscribe renee.gaudette@yale.edu

<u>Update Profile</u> | Constant Contact Data Notice

Sent byrenee.gaudette@yale.edupowered by

